Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923544 | 0.85 | PTK2 (0.56) | PTK2CYP1A2GAAHCAR3GRIN2B | |
| SCHEMBL16463469 | 0.85 | PTK2 (0.56) | PTK2CYP1A2GAAHCAR3GRIN2B | |
| SCHEMBL25702957 | 0.84 | GSK3B (0.46) | HCAR3GSK3BNNMTEPHX2PTPN1 | |
| SCHEMBL30320778 | 0.84 | GSK3B (0.46) | HCAR3GSK3BNNMTEPHX2PTPN1 | |
| SCHEMBL6576391 | 0.84 | ALDH1A1 (0.58) | PTK2CYP1A2GAAHCAR3GRIN2B | |
| SCHEMBL31661260 | 0.84 | HCAR3 (0.69) | HCAR3GSK3BNNMTPTPN1 | |
| SCHEMBL16865853 | 0.83 | HCAR3 (0.64) | HCAR3GSK3BNNMTPTPN1 | |
| SCHEMBL31661280 | 0.83 | HCAR3 (0.64) | HCAR3GSK3BNNMTPTPN1 | |
| SCHEMBL9772954 | 0.83 | ALDH1A1 (0.51) | HCAR3GSK3BDEGS1 | |
| SCHEMBL16463731 | 0.83 | PTK2 (0.53) | PTK2CYP1A2GAAHCAR3GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893280-B2 | 2,4-disubstituted thiazolyl derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| EP-1261607-B1 | 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060211704-A1 | 2,4-Disubstituted thiazolyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-7105550-B2 | 2,4-disubstituted thiazolyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-12 | — | — | US | disclosed |
| US-20030203897-A1 | 2,4-Disubstituted thiazolyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-30 | — | — | US | disclosed |
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0244728-A2 | Use of heteroarylethyl amines to stimulate animal growth, heteroarylethyl amines and process for their preparation | BAYER AG (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211704-A1 | 2,4-Disubstituted thiazolyl derivatives | IL4, PTGER4, PTGER3 | PTK2 1966/4885CYP1A2 147/4885GAA 4615/4885 |
| US-20030203897-A1 | 2,4-Disubstituted thiazolyl derivatives | IL4, PTGER4, PTGER1 | PTK2 1598/4885CYP1A2 120/4885GAA 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.